US
Blog
Current Health
Retatrutide produces up to 30.3% weight loss in Phase 3 trial
Retatrutide, a triple-hormone injection, produced up to 30.3% average weight loss in the phase 3 TRIUMPH-1 trial. Not yet approved in the UK.
Current Health
Why people on Mounjaro and Wegovy face stigma that ’dieters’ don’t
New research finds GLP-1 users are judged more harshly than dieters, and sometimes more than people who haven't lost weight. Here's what the study shows.
Current Health
New study: survodutide produces 16.6% weight loss in Phase 3 trial
Phase 3 trial: survodutide produced up to 16.6% weight loss in 76 weeks. How it compares to Mounjaro, Wegovy, and Wegovy 7.2 mg.
Current Health
New study: ultra-processed foods linked to more fat inside muscle, regardless of calorie intake
A new MRI study of 615 adults found higher ultra-processed food intake was linked to more fat stored inside muscle tissue, even when calories were matched.
Current Health
Why GLP-1 medications work better for some people than others
A Nature study of 27,885 people identified gene variants that predict GLP-1 weight loss and nausea risk, including one specific to Mounjaro users.
Current Health
New study: weight regain after stopping Ozempic and Mounjaro isn’t inevitable
A study of 8,000 patients found weight regain after stopping GLP-1 medications was far less than clinical trials predicted. Here's why.
As seen on
As seen on
